Company intelligence / Profile preview
ISOThrive
Manassas, Virginia, United Statespharma.isothrive.com ↗
- Ownership
- Private
- Employees
- ~11
- Development stage
- Phase 2
01
Overview
Currently conducting a Phase 2A clinical study for ISOT-101, a microbiome therapeutic for GERD. The study is expected to be completed by the end of Q1 2025. The company has received FDA IND approval to proceed directly to Phase 2.
- Therapeutic areas
- GastroenterologyOncology
- Modalities
- Microbiome therapeuticsPrebiotics
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Eastern Virginia Medical SchoolUniversity of VirginiaGeorge Mason University
Beyond the preview
Go deeper on ISOThrive.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ISOThrive.